Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: A weighted meta-analysis of seven randomised controlled trials including 5577 patients.

The first generation ABSORB BVS scaffold; to be or not to be? Neth Heart J (2017) 0.78

Adverse events with bioresorbable vascular scaffolds in routine percutaneous coronary interventions: "coup de théâtre" or unfinished play? J Thorac Dis (2017) 0.75

Measuring inconsistency in meta-analyses. BMJ (2003) 128.20

Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54

Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. N Engl J Med (2017) 5.42

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention (2015) 4.00

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet (2014) 3.47

Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet (2015) 3.44

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med (2015) 2.97

Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol (2015) 2.84

A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J (2015) 2.40

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet (2016) 2.11

Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol (2015) 1.75

Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. J Am Coll Cardiol (2016) 1.73

Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J (2015) 1.71

From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J (2011) 1.38

Everolimus-Eluting Bioresorbable Scaffolds versus Metallic Everolimus-Eluting Stents: Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol (2017) 0.90

Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention (2016) 0.89

Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials. Circ Cardiovasc Interv (2017) 0.87

Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv (2015) 0.86

Definite and probable bioresorbable scaffold thrombosis in stable and ACS patients. EuroIntervention (2015) 0.81

Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial. Int J Cardiol (2017) 0.81

Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry. JACC Cardiovasc Interv (2016) 0.80

Possible Mechanical Causes of Scaffold Thrombosis: Insights from Case Reports with Intracoronary Imaging. EuroIntervention (2016) 0.78

What determines long-term outcomes using fully bioresorbable scaffolds - the device, the operator or the lesion? EuroIntervention (2017) 0.78